Navigation Links
United BioSource Scientists, FDA, and Other Industry Leaders Present to Risk Management and Drug Safety Summit

Conference: How to Build Effective Global Programs Required by New Legislation

BETHESDA, Md., Nov. 19 /PRNewswire/ -- United BioSource Corporation's (UBC) Annette Stemhagen, DrPH, FISPE, and Gerald Faich, MD, MPH, FISPE, addressed the Risk Management and Drug Safety Summit held in Washington, DC, on October 28 and 29, along with Janet Woodcock, MD, Director, CDER, FDA; Jane Axelrad, Associate Director for Policy, CDER, FDA; Claudia Karwoski, acting director, Division of Risk Management Team, Office of Surveillance and Epidemiology, CDER; and other leading scientists from the pharmaceutical community.


Co-sponsored by UBC and FDA News, the two-day conference was designed to help drug and biologics manufacturers understand how to build effective global risk management and drug safety programs, in response to the FDA Amendments Act of 2007 (FDAAA) and new international regulations now under development.

Patrick Lindsay, UBC's Executive Vice President, said "UBC was pleased to join forces with FDA News to bring together this esteemed group of experts in risk management. We recognize how important it is to master the critical components of the FDAAA to optimize pharmaceutical products, both for the safety of patients and to create value for pharma and biotech companies."

Dr. Stemhagen, Vice President, Epidemiology and Risk Management, UBC, spoke about "Using Registries and Large Streamlined Studies (LSS) to Improve Post-Approval Safety Surveillance, Risk Assessment and Risk Management," reviewing key factors to consider before implementing a registry or LSSs, best practices for using registries as part of risk management planning, and real-world case studies using LSSs.

Dr. Faich, Senior Vice President, Epidemiology and Risk Management, UBC, co-moderated a session called "How Does the FDA Intend to Evaluate REMS (Risk Evaluation Mitigation Strategy)?" with Dr. Stemhagen and other industry leaders. This session evaluated how FDA's response to previously submitted REMS provides insight into how to create successful and compliant REMS.

Other speakers included:

  • Laurent Auclert, MD, Head, Risk Management Plan Unit, Global Pharmacovigilance & Epidemiology, sanofi-aventis

  • Cherif Benatti, MD, Vice President, Pharmacovigilance & Public Health, Vertex Pharmaceuticals

  • Carmen Bozic, Vice President, Drug Safety & Risk Management, Biogen Idec

  • John Ferguson, Vice President & Global Head, Pharmacovigilance & Medical Safety, Novartis Vaccines & Diagnostics

  • Joanna Haas, MD, MS, Vice President, Pharmacovigilance, Genzyme Corporation

  • Peter Pitts, Co-founder and President of Center for Medicine in the Public Interest and Senior Vice President, Health Affairs, Manning, Selvage & Lee

  • Donald Therasse, MD, Vice President, Global Patient Safety, Lilly Research Laboratories

"All conference presenters were mindful of the pressure on drug and biologics manufacturers in light of FDAAA's passage in late March 2007," noted Dr. Stemhagen. "Since then, FDA has mandated REMS for 31% of all new molecular entities and novel therapeutic biologics. In just the past seven months, we at UBC have seen a dramatic increase in the number of clients who have asked us to assist with REMS."

United BioSource Corporation (UBC) is a global pharmaceutical services organization that helps emerging and established life science companies develop and commercialize medical products. UBC specializes in offering new and innovative ways to study drugs and devices by providing expertise in science, strategy and execution.

UBC is headquartered in Bethesda, Maryland, with offices in the United States, Canada, Western Europe, Eastern Europe and South America. For more information, visit or call 866-458-1096.

CONTACT: Tess Drahzal, +1 (240) 644-0420,

SOURCE United BioSource Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
2. United States continues to have highest level of health spending
3. United Medicorp, Inc.s Shareholders Approve All Proposals
4. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
5. Medical Services International Received Its First Order for Testing By Regulatory Agencies in the United States
6. Peoples United Financial CEO Has Surgery
7. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
8. More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States
9. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
10. Universal Health Care Coverage in the United States
11. Women Deliver Conference to Feature United Nations Leaders
Post Your Comments:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... board certified facial plastic surgeon specializing in both surgical and non-surgical treatments, announced ... Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained and nationally ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... “While riding ... an inventor, from Bronx, N.Y. “I thought there had to be a convenient and ... the PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during cold or ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... cancer, I found that regular bras were incredibly uncomfortable," said an inventor from ... specialized bra." , She developed the patent-pending RECOVERY BRA for added comfort and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted to ... raising public awareness of the disorder while helping to bring expert medical care ... to bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... plc (NYSE: AGN ) today announced that it has ... Attorney General,s Office to end the litigation under ... the Attorney General over the decision of Forest Laboratories, Inc., ... now generic version of memantine immediate release tablets.  Under the ... counterclaims against New York , and has ...
(Date:11/25/2015)... 2015 Allergan plc (NYSE: AGN ... Therapeutics, a start-up  biotechnology company focused on the ... and funded by the F-Prime Biomedical Research Initiative ... an exclusive collaboration to support the discovery and ... (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... November 25, 2015 --> ... blood glucose devices was valued at $11,171.1 million in ... CAGR of 5.7% during 2015 - 2022. The global ... increasing prevalence of diabetes. In addition, the increase in ... also contributing to the growth of the market. Furthermore, ...
Breaking Medicine Technology: